Investing.com - Marinus Pharma (NASDAQ: MRNS) reported first quarter EPS of $-0.74, $0.12 worse than the analyst estimate of $-0.62. Revenue for the quarter came in at $7.19M versus the consensus estimate of $7.97M.
Guidance
Marinus Pharma sees FY 2024 revenue of $32.00M-$34.00M versus the analyst consensus of $42.73M.
Marinus Pharma's stock price closed at $9.24. It is up 8.71% in the last 3 months and up 30.65% in the last 12 months.
Marinus Pharma saw 4 positive EPS revisions and 3 negative EPS revisions in the last 90 days. See Marinus Pharma's stock price’s past reactions to earnings here.
According to InvestingPro, Marinus Pharma's Financial Health score is "fair performance".
Check out Marinus Pharma's recent earnings performance, and Marinus Pharma's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar